Ascidian Therapeutics is a biotechnology company developing exon-editing RNA therapeutics to target the underlying causes of disease.
By harnessing the RNA splicing machinery of a cell and combining it with large-scale DNA and RNA synthesis, deep-sequencing technologies, and clinically validated therapeutic delivery systems, Ascidian aims to restore normal protein function to deliver life-changing treatments to patients.
Ascidian’s first-of-its-kind RNA exon editing platform is designed to create a new class of medicines – to treat diseases not addressed by today’s gene editing technologies or RNA therapeutic approaches.
